Longitudinal Registry for Advanced Heart Failure Patients

NCT ID: NCT00364416

Last Updated: 2010-04-28

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 1466 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2002-10-31
• Study Completion Date: 2006-04-30

Brief Summary

The purpose of this study is to gather information to better understand the characteristics, medical management techniques and outcomes of patients with chronic severe Heart Failure (HF).

Detailed Description

This objectives of this observational registry are: to assess changes in patient quality of life as a function of medical management and disease progression as measured by the rate of death and rehospitalization, and assist with the optimization of heart failure (HF) management by providing information on the use of therapies proven to be effective and to describe practices of standard of care for chronic treatment of symptoms of HF outside the hospital and during hospitalization for acute episode with intravenous vasoactive medication (drugs which affect the blood vessels and muscle of the heart). Additional information which will be gathered include patient characteristics (age, sex, race, medical history, symptoms), infusion setting, type of medication, dose and frequency of medication and worsening of congestive heart failure disease. Participants in the study receive an unique patient-specific identifier and all available data will be analyzed. Observational Study - No investigational drug administered

Conditions

Heart Failure, Congestive; Heart Decompensation

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

001

Any treatment used to treat CHF

Intervention Type: OTHER

Clinical Outcomes of Chronic Decompensated Heart Failure patients

Interventions

Any treatment used to treat CHF

Clinical Outcomes of Chronic Decompensated Heart Failure patients

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age older than or equal to 18 years at the time of entry into the Registry
• Severe symptoms of HF at rest with marked limitation of physical activity continuously for at least 60 days prior to inclusion in the Registry
• Patient has been hospitalized 2 times in the past 12 months with a primary diagnosis of HF
• Patient's HF is refractory or relatively refractory to usual non-IV medications, as defined by having received one of the two following regimens for the treatment of HF in that last 60 days: 2 complete IV infusions, each lasting at least 2 hours, of either vasoactive (drugs having an effect on veins or arteries) or inotrope medications (drugs that makes the heart works better), or 3 IV diuretic (drugs that increase the elimination of urine) treatments

Exclusion Criteria

• History of any organ transplantation
• Patient is expected to die within the next 5 days
• Patient is seen for consultation or evaluation only, and is unlikely to receive follow-up care at the participating clinic/hospital
• Participation in a clinical study of the drug Natrecor

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Scios, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Scios

Principal Investigators

Scios, Inc. Clinical Trial

Role: STUDY_DIRECTOR

Scios, Inc.

Other Identifiers

CR005212

Identifier Type: -

Identifier Source: org_study_id